These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 32085891)

  • 1. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
    Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
    Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
    Mark M; Rusakiewicz S; Früh M; Hayoz S; Grosso F; Pless M; Zucali P; Ceresoli GL; Maconi A; Schneider M; Froesch P; Tarussio D; Benedetti F; Dagher J; Kandalaft L; von Moos R; Tissot-Renaud S; Schmid S; Metaxas Y
    ESMO Open; 2022 Jun; 7(3):100446. PubMed ID: 35427834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma.
    Dumoulin DW; Cantini L; Cornelissen R; Vink M; Klaase L; Slooff K; Tebayna N; Mankor JM; Baart SJ; Hendriks R; Dingemans AC; Willemsen M; Aerts JGJV
    Eur J Cancer; 2022 Sep; 172():357-366. PubMed ID: 35834843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
    Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
    Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
    Cortinovis D; Grosso F; Carlucci L; Zucali PA; Pasello G; Tiseo M; Sperandi F; Hollander L; Galli F; Torri V; Rulli E; Canova S; Maconi A; Bidoli P; Ceresoli GL; D'Incalci M;
    Clin Lung Cancer; 2021 Jul; 22(4):361-370.e3. PubMed ID: 32732073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA; Perrino M; Lorenzi E; Ceresoli GL; De Vincenzo F; Simonelli M; Gianoncelli L; De Sanctis R; Giordano L; Santoro A
    Lung Cancer; 2014 Jun; 84(3):265-70. PubMed ID: 24321581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases.
    Metaxas Y; Cathomas R; Mark M; von Moos R
    Lung Cancer; 2016 Dec; 102():136-138. PubMed ID: 27440191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
    Calabrò L; Morra A; Fonsatti E; Cutaia O; Fazio C; Annesi D; Lenoci M; Amato G; Danielli R; Altomonte M; Giannarelli D; Di Giacomo AM; Maio M
    Lancet Respir Med; 2015 Apr; 3(4):301-9. PubMed ID: 25819643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
    Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
    Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
    Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T
    J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
    Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
    J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
    Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
    Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
    Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
    Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
    Gregorc V; Gaafar RM; Favaretto A; Grossi F; Jassem J; Polychronis A; Bidoli P; Tiseo M; Shah R; Taylor P; Novello S; Muzio A; Bearz A; Greillier L; Fontana F; Salini G; Lambiase A; O'Brien M
    Lancet Oncol; 2018 Jun; 19(6):799-811. PubMed ID: 29753703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.
    Grosso F; Steele N; Novello S; Nowak AK; Popat S; Greillier L; John T; Leighl NB; Reck M; Taylor P; Planchard D; Sørensen JB; Socinski MA; von Wangenheim U; Loembé AB; Barrueco J; Morsli N; Scagliotti G
    J Clin Oncol; 2017 Nov; 35(31):3591-3600. PubMed ID: 28892431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
    Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
    Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lam WS; Creaney J; Chen FK; Chin WL; Muruganandan S; Arunachalam S; Attia MS; Read C; Murray K; Millward M; Spiro J; Chakera A; Gary Lee YC; Nowak AK
    Lung Cancer; 2020 Feb; 140():87-92. PubMed ID: 31901768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
    Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
    Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
    Fennell DA; Baas P; Taylor P; Nowak AK; Gilligan D; Nakano T; Pachter JA; Weaver DT; Scherpereel A; Pavlakis N; van Meerbeeck JP; Cedrés S; Nolan L; Kindler H; Aerts JGJV
    J Clin Oncol; 2019 Apr; 37(10):790-798. PubMed ID: 30785827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
    Canova S; Ceresoli GL; Grosso F; Zucali PA; Gelsomino F; Pasello G; Mencoboni M; Rulli E; Galli F; De Simone I; Carlucci L; De Angelis A; Belletti M; Bonomi M; D'Aveni A; Perrino M; Bono F; Cortinovis DL;
    ESMO Open; 2022 Dec; 7(6):100644. PubMed ID: 36463732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.